2-Furoyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 agonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 3, 2004, Pages 1124-1131

  McGuire, John J ^a,b   Saifeddine, Mahmoud ^a   Triggle, Chris R ^a   Sun, Kimberly ^a   Hollenberg, Morley D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 FUROYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLORNITHINAMIDE; CALCIUM; CINNAMOYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCYLORNITHINAMIDE; PEPTIDE DERIVATIVE; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 AGONIST; SERYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCINAMIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTERY CONSTRICTION; ARTICLE; BIOASSAY; CALCIUM CELL LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FEMORAL ARTERY; GENE EXPRESSION; HYPERPOLARIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

AMIDES; ANIMALS; AORTA; ELECTROPHYSIOLOGY; FEMORAL ARTERY; HUMANS; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; VASCULAR RESISTANCE;

EID: 2442702842     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.064584     Document Type: Article

References (20)

1. 2-derived peptide ligands. J Pharmacol Exp Ther 290:753-760.
2. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, and Seiler SM (1996) Development of potent thrombin receptor antagonist peptides. J Med Chem 39:4879-4887.
3. Coller BS, Springer KT, Scudder LE, Kutok JL, Ceruso M, and Prestwich GD (1993) Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem 268:20741-20743.
4. Compton SJ, Cairns JA, Palmer KJ, Al Ani B, Hollenberg MD, and Walls AF (2000) A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J Biol Chem 275:39207-39212.
5. Compton SJ, McGuire JJ, Saifeddine M, and Hollenberg MD (2002) Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta. Can J Physiol Pharmacol 80:987-992.
6. 1. J Pharmacol Exp Ther 288:671-678.
7. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJ, Hunter GD, McLean JS, McGarry F, et al. (2003) Essential role for proteinase-activated receptor-2 in arthritis. J Clin Investig 111:35-41.
8. Hollenberg MD and Compton SJ (2002) International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54:203-217.
9. Hollenberg MD and Saifeddine M (2001) Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol 79:439-442.
10. Hollenberg MD, Saifeddine M, and Al Ani B (1996) Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. Mol Pharmacol 49:229-233.
11. 1-targeted ligands. J Pharmacol Exp Ther 288:358-370.
12. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, and Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245-282.
13. Maryanoff BE, Santulli RJ, McComsey DF, Hoekstra WJ, Hoey K, Smith CE, Addo M, Darrow AL, and Andrade-Gordon P (2001) Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes. Arch Biochem Biophys 386:195-204.
14. 2. J Pharmacol Exp Ther 303:985-992.
15. McGuire JJ, Gui Y, Wang X, Loutzenhiser RD, Triggle CR, and Hollenberg MD (2003) Proteinase-activated receptor-2 (PAR2): release of an endothelium-derived hyperpolarizing factor distinct from that released by acetylcholine, in EDHF 2002 (Vanhoutte PM ed) pp 47-54, Taylor & Francis, London.
16. McGuire JJ, Hollenberg MD, Andrade-Gordon P, and Triggle CR (2002b) Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol 135:155-169.
17. McGuire JJ and Triggle CR (2003) Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor 2. Drug Dev Res 60:14-19.
18. Vergnolle N, Macnaughton WK, Al Ani B, Saifeddine M, Wallace JL, and Hollenberg MD (1998) Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci USA 95:7766-7771.
19. Vergnolle N, Wallace JL, Bunnett NW, and Hollenberg MD (2001) Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146-152.
20. Vu TK, Hung DT, Wheaton VI, and Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068.